Impact of pharmacy care upon adherence to cardiovascular medication a feasibility controlled trial by Mohammed Ali, ZS et al.
1 
 
Impact of Pharmacy Care upon Adherence to Cardiovascular Medicines: A Feasibility 
Pilot Controlled Trial 
Corresponding author: Zahraa S.MA Jalal:  Email: Zahraa.ali.11@ucl.ac.uk   
Zahraa Jalal1, Felicity Smith1, David Taylor1, Katherine Finlay2, Hemant Patel3 and Sotiris 
Antoniou4 
1Department of Practice and Policy, School of Pharmacy, University College London, UK 
2Department of Psychology The University of Buckingham, Buckingham 
3North-East London Local Pharmaceutical Committee, Brentwood, Essex  
4Pharmacy Department, Barts Heart Centre, Barts Health NHS Trust 
 
ClinicalTrials.gov Identifier: NCT01920009 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
Objective 
 
To investigate the feasibility and potential impact of a pharmacy care intervention, involving 
motivational interviews amongst patients with acute coronary syndrome, on adherence to 
medication and on health outcomes. 
 
Methods 
This article reports a prospective, interventional, controlled feasibility/pilot study.  Seventy one 
patients discharged from a London Heart Attack Centre following acute treatment for a coronary 
event were enrolled and followed up for six months.  Thirty two pharmacies from 6 London 
Boroughs were allocated into intervention or control sites.  The intervention was delivered by 
community pharmacists face-to-face in the pharmacy, or by telephone.  Consultations were 
delivered as part of the New Medicine Service or a Medication Usage Review.  They involved a 
15-20 minute motivational interview aimed at improving protective cardiovascular medicine 
taking. 
Results 
 
At 3 months there was a statistically significant difference in adherence between the intervention 
group (M= 7.7, SD=0.56) and the control group (M= 7.0, SD=1.85), (P= 0.026). At 6 months the 
equivalent figures were for the intervention group M=7.5, SD=1.47 and for the controls M= 6.1, 
SD=2.09 (P=0.004).  In addition, there was a statistically significant relationship between the 
level of adherence at 3 months and beliefs regarding medicines (P=0.028).  Patients who 
reported better adherence expressed positive beliefs regarding the necessity of taking their 
medicines.  However, given the small sample size, no statistically significant outcome difference 
in terms of recorded blood pressure and LDL-C was observed over the six months of the study.  
  
Conclusion  
The feasibility, acceptability and potentially positive clinical outcome of the intervention was 
demonstrated, long with a high level of patient acceptability.  It had a significant impact on 
cardiovascular medicine taking adherence.  But these findings must be interpreted with caution. 
The intervention should be tested in a larger trial to ascertain its full clinical utility.   
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Key Messages 
What is already known on this subject 
• Pharmacist interventions have been shown to be successful in enhancing adherence to cardiovascular 
medication and improving outcomes of cardiovascular diseases. 
• Improved adherence to secondary prevention medication for coronary heart disease would promote 
better clinical outcomes. 
• Motivational interviewing can be an effective approach to improve health behaviour in people with 
coronary risk factors. 
 
What this study adds 
  
• This pilot study suggests that a behavioural intervention, incorporating motivational interviewing and 
delivered in a community pharmacy setting,  can improve adherence to secondary prevention 
cardiovascular medication, and corresponding clinical outcomes for patients following a myocardial 
infarction. 
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Background 
Despite progress since the 1950s, cardiovascular disease (CVD) remains a significant cause of 
mortality and morbidity in the UK.  There are currently an estimated 2.3 million people living 
with CHD who are in need of secondary prevention medication [1]. Yet long-term adherence to 
secondary prevention therapies is poor. Reported adherence to medication regimens post 
Myocardial Infarction (MI) ranges from 13-60 per cent [2]. 
 
Research indicates that approximately a quarter to a third of CVD patients discontinue their 
medication [3] [4]. This problem is associated with drug wastage and, more importantly a loss of 
clinical benefit and potentially serious health consequences [5].  
 
There is robust evidence that consistent use of secondary prevention medication after a coronary 
event is associated with lower adjusted mortality as rates compared with those amongst subjects 
who are not consistent medicine takers [6].  For example, patients discontinuing clopidogrel 
within a month after hospital discharge following acute myocardial infarction and drug eluting 
stent placement are significantly more likely to have an adverse outcome in the subsequent 11 
months [7].  
 
Strategies to tackle non-adherence can involve community pharmacy service providers. In 
England, Medicine Use Reviews (MURs) were first instituted in 2005[8]. They are intended to 
help identify and address problems that patients experience in relation to taking medicines.  
More recently, the New Medicines Service (NMS) [9] was introduced in order to promote 
adherence in patients taking medicines for the first time for a range of long-term conditions.  
Both these services are NHS (The UK National Health Service) remunerated services of 
community pharmacists. 
 
Other strategies for supporting enhanced medicines usage involve motivational interviewing. 
This can be defined as a client-centred, directive, form of counselling intended to foster 
behavioural change by increasing awareness of ambiguities and internal dissonance [10]. 
Motivational interviewing has been employed in many clinical settings and with multiple patient 
groups. [11], [12], [13] 
 
Pharmacists are increasingly employing patient-centred approaches to support patients taking 
medicines for long-term conditions.  Yet there is currently no adequate evidence base regarding 
the feasibility and effectiveness of motivational interviewing to promote medication adherence in 
the pharmacy setting.  This study was carried out to address this shortcoming and to evaluate the 
potential effectiveness of a community pharmacy intervention for patients discharged following 
a myocardial infarction with secondary prevention medication.  It also explored issues relating to 
improving communication and collaboration between hospital and community pharmacists. 
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Objectives 
To investigate the potential impact on outcomes of a pharmacy care intervention involving 
hospital pharmacy referral to community pharmacy services and motivational interviewing on 
adherence to secondary prevention medication amongst recently discharged coronary heart 
disease patients  
 
Methods 
 
Design  
 
The study was designed as a prospective, feasibility/pilot, controlled trial. The primary outcome 
was adherence to cardiovascular medication (Figure 1).  
 
Study setting and Study population 
 
 
The study was undertaken in collaboration with community pharmacists in East London and the 
North East London Pharmaceutical Committee (NELLPC) and with practitioners and patients 
from a London Heart Attack Centre.  The study gained research ethical approval from the 
National Research Ethics Service Committee (North West – Preston), from the R &D Joint 
Research Management Office, Queen Mary Innovation Centre, and from the R&D Office, 
University College London.  The study population included coronary heart disease patients with 
a discharge diagnosis of Acute Coronary Syndrome (ACS).  
 
Recruitment  
There were two stages of recruitment; recruitment of pharmacies and recruitment of patients.  
Community pharmacists/pharmacies were recruited through NELLPC and assigned as below to 
either the intervention or control group.  The inclusion criteria were:  (1) Pharmacists willing to 
counsel patients and interested in attending further training; (2) have a consultation area and have 
access to a telephone (land line or mobile) ;(3) the pharmacists were knowledgeable about the 
NMS and MUR, and had contacts with or were willing to contact general practitioners and also 
willing to contact patients to invite them for a consultation.   
 
Allocation to intervention and control groups 
Whilst simple randomisation of the entire sample was not possible, procedures were adopted to 
ensure comparability of the intervention and control groups for this study. Pharmacy recruitment 
was all done through NELLPC.  Pharmacists informed of study by two different routes.  Firstly, 
by email 22 pharmacies responded that they wished to take part. These were randomised to 
intervention and control by an independent statistician at UCL School of Pharmacy.  This 
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process was concealed from the researcher and the research team and was performed at 
pharmacy level to avoid contamination of controls.  
To achieve sufficient numbers a second group were invited to participate during a professional 
meeting and 10 pharmacies met the inclusion criteria.  As the dates of motivational interview 
training had had to be set in advance, pharmacists wishing to take part and able to attend the pre-
determined dates were allocated to the intervention group. The control group was a matched 
sample drawn from remaining pharmacists who expressed a wish to take part.  See Figure 2. 
Eligible patients were prior to discharge given introductory information about the study by the 
researcher and supplied with further details as requested. They were then asked if they would 
like to participate. The full eligibility and exclusion criteria are described in Supplementary 
Table 1.  After recruitment, patients were assigned into groups according to the primary care 
pharmacy at which they usually refill their prescriptions.  Patients who normally refill their 
prescription from the intervention pharmacies were assigned to the intervention group and 
patients who regularly refilled their prescription in the pharmacies that were control sites were 
assigned to the control group. 
Blinding   
The research pharmacist responsible for the data analysis was blind to the above group 
allocations.  The General Practitioners/Practices from which data regarding blood pressures and 
LDL-C levels were collected were also blind, unless referral of a patient by a community 
pharmacist took place.  However, due to the nature of the intervention it was not possible to 
blind the hospital and community pharmacists delivering the intervention or the patients 
receiving it. 
 
Sample size  
Power calculations were based on the findings of previous studies in which the primary outcome 
was adherence.  For instance, a similar study [14] reported a 33 per cent increase in adherence 
with a margin error of 5 per cent and confidence interval 95 per cent. Given these and allied data 
the enrolment target was set at 200 patients.  
Pharmacist training 
Pharmacists in the intervention delivery group participated in a two day training session on 
motivational interviewing, followed by a subsequent booster session, given by an expert 
psychologist (KF), all the training sessions on motivational interviewing including the booster 
session were completed before inclusion of patients.  An additional training session on the use of 
secondary prevention medicines after a myocardial infarction was given by a consultant 
pharmacist (SA).  
 
Liaison with General Practitioners  
The GPs were asked for their written consent to providing the results of blood pressure 
measurements and LDL-C levels during the duration of the study with patient consent.   
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The intervention  
 
The intervention was developed on the basis of a previous systematic review [15].  A ‘consultation 
chart’ (a pro forma guide the motivational interview process) was developed by referring to a 
previous randomised controlled trial involving hypertensive patients [16] which generated 
statistically significant impacts on adherence.  In this instance trained research assistants rather 
than pharmacists used motivational interviewing techniques. The intervention was designed to 
include elements of motivational interviews and to be integrated into the existing NMS and 
MUR pharmacy services so that the participating community pharmacists would be able to claim 
funding for their work.  
On discharge patients receiving the intervention were initially given usual care from a hospital 
pharmacist.  This consisted of a review of medications use, counselling on secondary prevention 
and any other additional prescribed medication usage, an antiplatelet medication leaflet and 
referral to cardiac rehabilitation.  Patients were subsequently contacted by a pharmacist to 
arrange a community pharmacy consultation. 
The first community pharmacy consultation typically took place at around 2 weeks after hospital 
discharge on either a face to face basis or by telephone as recent evidence shows that 
motivational interviewing can be effectively delivered by telephone [17] and lasted for 15-20 
minutes. The substance of these sessions is detailed in Supplementary Box 1, also comparison of 
motivational interviewing with traditional counselling can be found in Supplementary Table 2.  
 
The control group 
On discharge control group patients received usual care from a hospital pharmacist. As described 
above.  
 
Outcome measures and Data collection  
 
The primary outcome measure used was self-reported adherence with the coronary artery disease 
medication regimen prescribed, assessed via the Morisky Medication Adherence Scale 
MMAS8[18]. The Beliefs about Medicines Questionnaire-Specific BMQ-S [19] was also used at 3 
months after discharge; to evaluate the effect of the intervention on patients beliefs regarding 
their medication and to examine the relationship between patients’ beliefs regarding their 
medicines and adherence, this study did not evaluate changes in patients’ beliefs over time.  
Secondary outcome measures included blood pressure and LDL-C. Baseline data collected from 
the hospital included gender, age, diagnosis, blood pressure, LDL-C, ethnicity, post code and GP 
practice, all patients enrolled in the study were discharged on four classes of medication 
(antiplatelets, beta blockers, ACE inhibitors or ARBs and statins) as recommended for secondary 
care of patients following a myocardial infarction [20].  Data collection took place at two weeks 
after hospital discharge and at 3and 6 months (figure 1). 
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Analysis  
 
Data was analysed by using the Statistical Package for the Social Sciences (SPSS) version 22 for 
Windows.  An independent T-test was used to compare the differences in the intervention group 
and control group adherence means and also to compare the differences between the blood 
pressures and LDL-C levels (Significance was set at the 5 percent level). A chi-square test was 
performed to examine the relationship between beliefs about medication and adherence to the 
cardiac medication at 3 months. The scores from the BMQ-S were handled according to standard 
procedures for analysis of the questionnaire [19].  
 
 
 
Results  
 
In the 4 months available for recruitment for this study 71 patients were enrolled consecutively.  
Recruitment is commonly one of the biggest challenges for any study.  In this instance it was 
undertaken by a single researcher.  On average it was possible to recruit 2- 3 patients per day, 
excluding those occasions on which no eligible patients presented.  Out of a total of 233 patients 
assessed for eligibility only 14 individuals refused to participate. Others were excluded because 
they did not meet the inclusion criteria as illustrated in the consort diagram– see Figure 3 
The NHS users recruited were predominantly male (76%) and as shown in Supplementary Table 
3, most were in their sixties and seventies.  It was found that 51 of the patients involved had had 
an ST-Elevation Myocardial Infarction (STEMI). The remaining 20 had suffered a Non ST-
Elevation Myocardial Infarction (NSTEMI).  
 
 
As a feasibility/pilot study, this was not powered to measure clinical outcomes and was designed 
only to provide an indication of potential effectiveness. Hence the findings presented here should 
be interpreted with caution.   
 
 
Impact on adherence 
 
As indicated in Figure 4 there was at baseline no difference in self-reported adherence rates 
between the intervention group (M=7.45, SD=0.79) and the control group (M=7.5, SD=0.93) 
(P=0.85).  However, at 3 months there was a statistically significant difference in adherence 
between the intervention group (M= 7.7, SD=0.56) and the control group (M= 7.0, SD=1.85), 
(P= 0.026).  There was also a statistically significant difference at 6 months between the 
intervention group (M=7.5 (93.75%), SD=1.47) and the controls (M= 6.1 (76.25%), SD=2.09) 
(P=0.004).  Note: (M=Mean, SD=Standard Deviation) 
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Beliefs about Medicines  
 
There was a statistically significant relationship between the level of adherence at 3 months and 
the beliefs regarding medicines as evaluated by the BMQ-S (P=0.028).  Patients with greater 
levels of self-reported adherence showed more positive beliefs regarding the necessity of their 
medicines.    
 
Results on clinical outcomes: blood pressure and LDL-C 
 
It was disappointing that for both BP and LDL-C around two-thirds of patients in both groups 
did not have a follow-up evaluation from their GPs.  This may help explain why at 3 months 
there was no statistically significant difference between the intervention group (M=127, SD= 20) 
and the control group in systolic blood pressure (M= 121, SD=20), P=0.3.   
 
Similarly at 6 months there was no statistically significant result between the intervention group 
(M=132, SD= 11) and the control group (M=129, SD= 12), P=0.6 (Figure 4).  Nevertheless, 
systolic blood pressure in the intervention group at 3 months decreased by 5 mmHg and at 6 
months returned to the same as baseline.  By contrast, Figure 4 also shows, in the control group 
systolic blood pressure had decreased by 3 mmHg at 3 months but increased by 5mmHg at 6 
months. 
 
Likewise, there was no significant difference in diastolic blood pressure between the intervention 
group at baseline (M= 74, SD=7.2) and the control group (M=73, SD= 11), P=0.8.  At 3 months 
there was again no statistically significant difference between the intervention group (M=73, 
SD= 11.5) and the controls (M=72, SD= 9.9), P=0.84.  At 6 months there was similarly no 
statistically significant result in the intervention group the figures were (M=68, SD= 11.7) and in 
the controls they were (M=75, SD=4.8), P=0.2. Nevertheless, at six months mean diastolic blood 
pressure in the intervention group had decreased by 6mmHg from baseline. In the control group 
diastolic blood pressure had by then increased by 2 mmHg from baseline.  
 
 
With regard to the LDL cholesterol levels reported, there was no statistically significant 
difference between the intervention group’s LDL-C at baseline (M=2.75, SD= 1.05) and the 
control group figures (M=2.79, SD=1.4), P=0.9.  At six months there was a 0.79 mmol/l 
difference in LDL-C between the intervention group and control group (Figure 4).  However, 
although suggestive of a material difference this result was once again non-significant, possibly 
because of the small numbers of subjects for whom data were available.  
 
    
 
Discussion  
 
This study reports positive findings regarding the potential outcomes of the community 
pharmacy intervention investigated.  Numerous studies have examined patients’ views on 
services provided by community pharmacists.  It has been commonly found that patient 
awareness of the pharmacist’s role outside that of dispensing and non-prescription drug supply is 
generally low. This could to date have led to an under-utilisation of pharmacist provided clinical 
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services [21] [22].  Initiatives like the study reported here may over time enhance awareness of the 
value of pharmacy services in ‘serious’ contexts like post-hospital discharge following a cardiac 
event. Such initiatives might also contribute to the uptake and utility of existing services (ie the 
NMS and MURs), and promote improved hospital and community pharmacy communication. 
In the latter context, patients’ discharge summaries were forwarded from the participating 
hospital pharmacy to community pharmacists.  Community pharmacy access to patients’ health 
care records is not as yet usually available in the UK or elsewhere. There is evidence that this 
restricts the capacity of pharmacists’ interventions to improve adherence and resolve other 
medication related problems [23].  This study demonstrates the potential importance of record 
sharing between community and hospital pharmacists in improving patient care. The supply of 
discharge summaries to community pharmacies was achieved by using secure hospital emails 
and with patient consent.   All the stakeholders involved, including the service users taking part, 
supported the supply of discharge summaries to community pharmacies.  This finding is in line 
with the approach advocated by the Royal Pharmaceutical Society (RPS) (2014). The RPS has 
recently launched ‘a hospital referral to community pharmacy innovators’ Toolkit developed in 
response to the report ‘Now or Never: Shaping Pharmacy for the Future’ [24].  In the Society’s 
view referrals from hospital to community pharmacies could become routine practice within five 
years.   
 
After six months self-reported medication adherence amongst those receiving motivational 
support from community pharmacist was 17 per cent greater than that recorded by control 
patients. This result can be compared to a recent US study [25] that found that a phone-based 
motivational interview improved adherence in the case of antiplatelet medicines by 14% (p < 
0.01).  It is also similar in magnitude to the reported effect of automated text messaging when 
used to prompt adherence to cardiovascular preventive treatment [26]. Other research studies have 
failed to find similar benefits in relation to the treatment of people who have experienced strokes 
or other forms of vascular disease [27][28]. Nevertheless, there is mounting reason to believe that 
greater use of well- targeted motivational interventions by community pharmacists could prove 
to be of substantive value in today’s environment. It is also possible that combinations of 
different types of approach to enhancing medication taking in high risk patient groups could have 
even greater effects. 
In this study a statistically significant relationship was found between reported adherence and 
medicine takers’ beliefs regarding the necessity of taking their prescribed treatments. Although 
there remain uncertainties regarding the causal links underpinning such observations, our 
findings are consistent with other research undertaken in the UK and elsewhere [29][30]. Investing 
in pharmacy led interventions to further promote awareness of the value of taking medicines in 
high risk therapeutic situations like post MI care has the potential to contribute cost effectively to 
improved health outcomes [31-34]. 
However, no statistically significant difference in the proportion of patients achieving BP and 
LDL-C reduction targets was found in this trial, which was not adequately powered to identify 
such effects. To date, most other similar studies have also failed to demonstrate statistically 
significant results in relation to such proxy clinical outcomes [35-38].  A relatively recent review 
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[35] concluded that too few pharmacy based trials are available in this area, and that further larger 
scale quantitative research involving CVD patients should be conducted.  
More qualitative work examining pharmacists’ experiences of using motivational interviews to 
enhance adherence should also prove useful.  In addition, after a life changing event such as a 
myocardial infarction many patients appear to welcome the additional primary care support that 
appropriately skilled community pharmacists are capable of providing. 
 
The positive responses of GPs involved in this investigation are also informative. Some previous 
research has indicated that GPs often tend to have negative attitudes towards extending 
community pharmacists’ clinical roles [39].  Yet the uptake and outcomes of community 
pharmacy services such as the intervention evaluated here are likely to improve when they are 
endorsed by GPs and effectively integrated with other primary care services. The findings of this 
research indicate that, in addition to recent measures aimed at encouraging the employment of 
pharmacists in GP surgeries, innovative approaches to developing community pharmacy 
contributions to the care of patients in need of better overall primary care services are also worth 
further investigation. 
 
This study’s main limitations relate to the small sample size and that it was focused on 
improving care in just one area of North East London; also it included a single centre this limits 
its perceived effectiveness in different locations and patient populations and also limits the 
confidence with which its findings can be generalised.  Other limitations; it was not possible to 
formally assess the extent to which all elements of motivational interviews were followed in the 
delivery of the intervention and ideally, measures of adherence that reduce reliance on self-
reported data would also have been valuable.  The strengths of the study that this article reports, 
which was designed as a feasibility pilot controlled trial, include that it used well validated 
instruments such as the Morisky Scale questionnaire and the BMQ, and that effective blinding 
procedures were put in place.  
 
Conclusion  
 
This work indicates how enhanced pharmaceutical care could help further improve adherence to 
medicines and health outcomes in relation to using medicines for preventive purposes amongst 
patients recovering from acute coronary events.  Moving further towards assuring the 
optimisation of medicines use in this and other contexts is likely to demand the organisation of a 
larger multicentre randomised control trial or trials, the design of which should be informed by 
the findings of this feasibility study.  
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